Targeted Brain Derived Neurotropic Factors (BDNF) Delivery across the Blood-Brain Barrier for Neuro-Protection Using Magnetic Nano Carriers: An In-Vitro Study
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Parenteral use of drugs; such as opiates exert immunomodulatory effects and serve as a cofactor in the progression of HIV-1 infection, thereby potentiating HIV related neurotoxicity ultimately leading to progression of NeuroAIDS. Morphine exposure is known to induce apoptosis, down regulate cAMP response element-binding (CREB) expression and decrease in dendritic branching and spine density in cultured cells. Use of neuroprotective agent; brain derived neurotropic factor (BDNF), which protects neurons against these effects, could be of therapeutic benefit in the treatment of opiate addiction. Previous studies have shown that BDNF was not transported through the blood brain barrier (BBB) in-vivo.; and hence it is not effective in-vivo. Therefore development of a drug delivery system that can cross BBB may have significant therapeutic advantage. In the present study, we hypothesized that magnetically guided nanocarrier may provide a viable approach for targeting BDNF across the BBB. We developed a magnetic nanoparticle (MNP) based carrier bound to BDNF and evaluated its efficacy and ability to transmigrate across the BBB using an in-vitro BBB model. The end point determinations of BDNF that crossed BBB were apoptosis, CREB expression and dendritic spine density measurement. We found that transmigrated BDNF was effective in suppressing the morphine induced apoptosis, inducing CREB expression and restoring the spine density. Our results suggest that the developed nanocarrier will provide a potential therapeutic approach to treat opiate addiction, protect neurotoxicity and synaptic density degeneration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bourtchuladze, R., Frenguelli, B., Blendy, J., Cioffi, D., Schutz, G., & Silva, A. J. (1994) · Cell · doi:10.1016/0092-8674(94)90400-6 · Cited by 1,800
BDNF function in adult synaptic plasticity: The synaptic consolidation hypothesis
Bramham, C. R., & Messaoudi, E. (2005) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2005.06.003 · Cited by 1,193
Poduslo, J. F., & Curran, G. L. (1996) · Molecular Brain Research · doi:10.1016/0169-328x(95)00250-v · Cited by 614
Substance use disorder among older adults in the United States in 2020
Han, B., Gfroerer, J. C., Colliver, J. D., & Penne, M. A. (2009) · Addiction · doi:10.1111/j.1360-0443.2008.02411.x · Cited by 337 · cited 5×
“Drugs of abuse such as opiates, cocaine, methamphetamine are frequently being used by individuals infected with HIV-1 [1].”
BackgroundInfluentialThoenen, H., & Sendtner, M. (2002) · Nature Neuroscience · doi:10.1038/nn938 · Cited by 336 · cited 1×
“Clinical trials have demonstrated that systemic deliveries at doses that are sufficiently high to result in therapeutic levels within the CNS parenchyma also result in significant systemic side-effects [49].”
BackgroundReversal of long-term dendritic spine alterations in Alzheimer disease models
Smith, D. L., Pozueta, J., Gong, B., Arancio, O., & Shelanski, M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908706106 · Cited by 229
Kwon, M., Fernandez, J. R., Zegarek, G. F., Lo, S. B., & Firestein, B. L. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.6785-10.2011 · Cited by 115
Research works printed but not linked: 65
- CJ Guo, 2002, Morphine enhances HIV infection of human blood mononuclear phagocytes through modulation of beta-chemokines and CCR5 receptor, J Investig Med, 50, 435, 10.1136/jim-50-06-03 · DOI
- V Purohit, 2011, Drugs of abuse, dopamine, and HIV-associated neurocognitive disorders/HIV-associated dementia, Mol Neurobiol, 44, 102, 10.1007/s12035-011-8195-z · DOI
- A Mansour, 1995, Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications, Trends Neurosci, 18, 22, 10.1016/0166-2236(95)93946-U · DOI · Paper page
- DR Wallace, 2006, HIV neurotoxicity: potential therapeutic interventions, J Biomed Biotechnol, 2006, 65741, 10.1155/JBB/2006/65741 · DOI
- MP Nair, 1997, Immunoregulatory effects of morphine on human lymphocytes, Clin Diagn Lab Immunol, 4, 127, 10.1128/CDLI.4.2.127-132.1997 · DOI
- D Yin, 1999, Fas-mediated cell death promoted by opioids, Nature, 397, 218, 10.1038/16612 · DOI · Paper page
- PC Singhal, 1998, Morphine enhances macrophage apoptosis, J Immunol, 160, 1886, 10.4049/jimmunol.160.4.1886 · DOI · Paper page
- SG Ayre, 1989, New approaches to the delivery of drugs to the brain, Med Hypotheses, 29, 283, 10.1016/0306-9877(89)90113-8 · doi:10.1016/0306-9877(89)90113-8
- AA Hurwitz, 1994, The role of the blood-brain barrier in HIV infection of the central nervous system, Adv Neuroimmunol, 4, 249, 10.1016/S0960-5428(06)80263-9 · DOI
- AL Betz, 1986, Specialized properties and solute transport in brain capillaries, Annu Rev Physiol, 48, 241, 10.1146/annurev.ph.48.030186.001325 · DOI · Paper page
- K Itoh, 2000, Neuronal damage of the substantia nigra in HIV-1 infected brains, Acta Neuropathol, 99, 376, 10.1007/s004010051139 · DOI
- GJ Wang, 2004, Decreased brain dopaminergic transporters in HIV-associated dementia patients, Brain, 127, 2452, 10.1093/brain/awh269 · DOI · Paper page
- RL Nosheny, 2007, Brain-derived neurotrophic factor prevents the nigrostriatal degeneration induced by human immunodeficiency virus-1 glycoprotein 120 in vivo, Eur J Neurosci, 25, 2275, 10.1111/j.1460-9568.2007.05506.x · DOI
- A Bachis, 2003, Brain-derived neurotrophic factor inhibits human immunodeficiency virus-1/gp120-mediated cerebellar granule cell death by preventing gp120 internalization, J Neurosci, 23, 5715, 10.1523/JNEUROSCI.23-13-05715.2003 · DOI
- I Mocchetti, 2007, Brain-derived neurotrophic factor prevents human immunodeficiency virus type 1 protein gp120 neurotoxicity in the rat nigrostriatal system, Ann N Y Acad Sci, 1122, 144, 10.1196/annals.1403.010 · DOI
- C Hyman, 1991, BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra, Nature, 350, 230, 10.1038/350230a0 · DOI · Paper page
- CA Altar, 1992, Brain-derived neurotrophic factor augments rotational behavior and nigrostriatal dopamine turnover in vivo, Proc Natl Acad Sci U S A, 89, 11347, 10.1073/pnas.89.23.11347 · DOI · Paper page
- LA Mamounas, 1995, Brain-derived neurotrophic factor promotes the survival and sprouting of serotonergic axons in rat brain, J Neurosci, 15, 7929, 10.1523/JNEUROSCI.15-12-07929.1995 · DOI · Paper page
- BH Han, 2000, BDNF blocks caspase-3 activation in neonatal hypoxia-ischemia, Neurobiol Dis, 7, 38, 10.1006/nbdi.1999.0275 · DOI · Paper page
- WM Pardridge, 2007, Blood-brain barrier delivery, Drug Discov Today, 12, 54, 10.1016/j.drudis.2006.10.013 · DOI · Paper page
- WM Pardridge, 1998, Combined use of carboxyl-directed protein pegylation and vector-mediated blood-brain barrier drug delivery system optimizes brain uptake of brain-derived neurotrophic factor following intravenous administration, Pharm Res, 15, 576, 10.1023/A:1011981927620 · DOI
- SS Suri, 2007, Nanotechnology-based drug delivery systems, J Occup Med Toxicol, 2, 16, 10.1186/1745-6673-2-16 · DOI · Paper page
- ZM Saiyed, 2007, Activity and stability of alkaline phosphatase (ALP) immobilized onto magnetic nanoparticles (Fe3O4), J Biotechnol, 131, 240, 10.1016/j.jbiotec.2007.06.017 · DOI
- ZM Saiyed, 2007, Extraction of DNA from agarose gel using magnetic nanoparticles (magnetite or Fe3O4), Anal Biochem, 363, 288, 10.1016/j.ab.2007.01.008 · doi:10.1016/j.ab.2007.01.008
- A Boyum, 1968, Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g, Scand J Clin Lab Invest, Suppl 97, 77
- N Gandhi, 2010, Interactive role of human immunodeficiency virus type 1 (HIV-1) clade-specific Tat protein and cocaine in blood-brain barrier dysfunction: implications for HIV-1-associated neurocognitive disorder, J Neurovirol, 16, 294, 10.3109/13550284.2010.499891 · DOI
- Y Persidsky, 1997, A model for monocyte migration through the blood-brain barrier during HIV-1 encephalitis, J Immunol, 158, 3499, 10.4049/jimmunol.158.7.3499 · DOI · Paper page
- SD Mahajan, 2005, Morphine modulates chemokine gene regulation in normal human astrocytes, Clin Immunol, 115, 323, 10.1016/j.clim.2005.02.004 · DOI
- Y Xia, 2010, Brain-derived neurotrophic factor prevents phencyclidine-induced apoptosis in developing brain by parallel activation of both the ERK and PI-3K/Akt pathways, Neuropharmacology, 58, 330, 10.1016/j.neuropharm.2009.10.009 · DOI · Paper page
- Y Li, 2007, Chronic morphine exposure alters the dendritic morphology of pyramidal neurons in visual cortex of rats, Neurosci Lett, 418, 227, 10.1016/j.neulet.2007.03.023 · DOI
- CA Chapleau, 2008, The actions of BDNF on dendritic spine density and morphology in organotypic slice cultures depend on the presence of serum in culture media, J Neurosci Methods, 169, 182, 10.1016/j.jneumeth.2007.12.006 · DOI
- S Roy, 1996, Effects of opioids on the immune system, Neurochem Res, 21, 1375, 10.1007/BF02532379 · DOI · Paper page
- GB Stefano, 1996, Opioid and opiate immunoregulatory processes, Crit Rev Immunol, 16, 109, 10.1615/CritRevImmunol.v16.i2.10 · DOI · Paper page
- SA Strathdee, 2010, Epidemiology of HIV among injecting and non-injecting drug users: current trends and implications for interventions, Curr HIV/AIDS Rep, 7, 99, 10.1007/s11904-010-0043-7 · DOI · Paper page
- SR Alcala-Barraza, 2010, Intranasal delivery of neurotrophic factors BDNF, CNTF, EPO, and NT-4 to the CNS, J Drug Target, 18, 179, 10.3109/10611860903318134 · DOI · Paper page
- HJ James, 1999, Expression of caspase-3 in brains from paediatric patients with HIV-1 encephalitis, Neuropathol Appl Neurobiol, 25, 380, 10.1046/j.1365-2990.1999.00195.x · doi:10.1046/j.1365-2990.1999.00195.x
- GA Garden, 2002, Caspase cascades in human immunodeficiency virus-associated neurodegeneration, J Neurosci, 22, 4015, 10.1523/JNEUROSCI.22-10-04015.2002 · DOI · Paper page
- 2001, Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations, Clin Pharmacokinet, 40, 907, 10.2165/00003088-200140120-00003 · DOI · Paper page
- AL Betz, 1978, Polarity of the blood-brain barrier: neutral amino acid transport into isolated brain capillaries, Science, 202, 225, 10.1126/science.211586 · DOI · Paper page
- AL Betz, 1980, Polarity of the blood-brain barrier: distribution of enzymes between the luminal and antiluminal membranes of brain capillary endothelial cells, Brain Res, 192, 17, 10.1016/0006-8993(80)91004-5 · DOI · Paper page
- RJ Mandel, 1999, Nerve growth factor expressed in the medial septum following in vivo gene delivery using a recombinant adeno-associated viral vector protects cholinergic neurons from fimbria-fornix lesion-induced degeneration, Exp Neurol, 155, 59, 10.1006/exnr.1998.6961 · DOI
- B Blits, 2003, Adeno-associated viral vector-mediated neurotrophin gene transfer in the injured adult rat spinal cord improves hind-limb function, Neuroscience, 118, 271, 10.1016/S0306-4522(02)00970-3 · DOI
- LR Williams, 1986, Continuous infusion of nerve growth factor prevents basal forebrain neuronal death after fimbria fornix transection, Proc Natl Acad Sci U S A, 83, 9231, 10.1073/pnas.83.23.9231 · DOI · Paper page
- GA Silva, 2007, Nanotechnology approaches for drug and small molecule delivery across the blood brain barrier, Surg Neurol, 67, 113, 10.1016/j.surneu.2006.08.033 · DOI
- ZM Saiyed, 2010, Magnetic nanoformulation of azidothymidine 5′-triphosphate for targeted delivery across the blood-brain barrier, Int J Nanomedicine, 5, 157
- B Chertok, 2008, Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors, Biomaterials, 29, 487, 10.1016/j.biomaterials.2007.08.050 · DOI · Paper page
- A Ito, 2005, Medical application of functionalized magnetic nanoparticles, J Biosci Bioeng, 100, 1, 10.1263/jbb.100.1 · DOI · Paper page
- C Alexiou, 2006, Targeting cancer cells: magnetic nanoparticles as drug carriers, Eur Biophys J, 35, 446, 10.1007/s00249-006-0042-1 · DOI · Paper page
- AS Lubbe, 1996, Preclinical experiences with magnetic drug targeting: tolerance and efficacy, Cancer Res, 56, 4694
- SG Kwon, 2007, Kinetics of monodisperse iron oxide nanocrystal formation by “heating-up” process, J Am Chem Soc, 129, 12571, 10.1021/ja074633q · DOI · Paper page
- ZM Saiyed, 2009, AZT 5′-triphosphate nanoformulation suppresses human immunodeficiency virus type 1 replication in peripheral blood mononuclear cells, J Neurovirol, 15, 343, 10.1080/13550280903062813 · DOI
- M Kaul, 2001, Pathways to neuronal injury and apoptosis in HIV-associated dementia, Nature, 410, 988, 10.1038/35073667 · DOI · Paper page
- R Goswami, 1998, Cyclic AMP protects against staurosporine and wortmannin-induced apoptosis and opioid-enhanced apoptosis in both embryonic and immortalized (F-11kappa7) neurons, J Neurochem, 70, 1376, 10.1046/j.1471-4159.1998.70041376.x · DOI
- PC Singhal, 1999, Morphine promotes apoptosis in Jurkat cells, J Leukoc Biol, 66, 650, 10.1002/jlb.66.4.650 · doi:10.1002/jlb.66.4.650
- DO Freier, 1993, Morphine-induced alterations in thymocyte subpopulations of B6C3F1 mice, J Pharmacol Exp Ther, 265, 81, 10.1016/S0022-3565(25)38147-4 · doi:10.1016/s0022-3565(25)38147-4
- BA Fuchs, 1993, Morphine induces apoptosis in murine thymocytes in vivo but not in vitro: involvement of both opiate and glucocorticoid receptors, J Pharmacol Exp Ther, 266, 417, 10.1016/S0022-3565(25)38348-5 · doi:10.1016/s0022-3565(25)38348-5
- R Bernabeu, 1997, Involvement of hippocampal cAMP/cAMP-dependent protein kinase signaling pathways in a late memory consolidation phase of aversively motivated learning in rats, Proc Natl Acad Sci U S A, 94, 7041, 10.1073/pnas.94.13.7041 · DOI · Paper page
- SM Taubenfeld, 1999, A molecular correlate of memory and amnesia in the hippocampus, Nat Neurosci, 2, 309, 10.1038/7217 · DOI
- M Cammarota, 2000, Learning-associated activation of nuclear MAPK, CREB and Elk-1, along with Fos production, in the rat hippocampus after a one-trial avoidance learning: abolition by NMDA receptor blockade, Brain Res Mol Brain Res, 76, 36, 10.1016/S0169-328X(99)00329-0 · DOI · Paper page
- H Viola, 2000, Phosphorylated cAMP response element-binding protein as a molecular marker of memory processing in rat hippocampus: effect of novelty, J Neurosci, 20, RC112, 10.1523/JNEUROSCI.20-23-j0002.2000 · DOI · Paper page
- M Alonso, 2005, Endogenous BDNF is required for long-term memory formation in the rat parietal cortex, Learn Mem, 12, 504, 10.1101/lm.27305 · DOI · Paper page
- F Sarti, 2007, Acute cocaine exposure alters spine density and long-term potentiation in the ventral tegmental area, Eur J Neurosci, 26, 749, 10.1111/j.1460-9568.2007.05689.x · DOI · Paper page
- M Frankfurt, 2011, Cocaine alters dendritic spine density in cortical and subcortical brain regions of the postpartum and virgin female rat, Synapse, 65, 955, 10.1002/syn.20918 · DOI · Paper page
- EJ Nestler, 2001, Molecular basis of long-term plasticity underlying addiction, Nat Rev Neurosci, 2, 119, 10.1038/35053570 · DOI · Paper page
- TE Robinson, 1999, Alterations in the morphology of dendrites and dendritic spines in the nucleus accumbens and prefrontal cortex following repeated treatment with amphetamine or cocaine, Eur J Neurosci, 11, 1598, 10.1046/j.1460-9568.1999.00576.x · DOI · Paper page
Cited by
Drug Delivery Systems, CNS Protection, and the Blood Brain Barrier
Upadhyay, R. K. (2014) · BioMed Research International · doi:10.1155/2014/869269 · Cited by 528
Astrocytic modulation of blood brain barrier: perspectives on Parkinson’s disease
Cabezas, R., Ãvila, M., Gonzalez, J., El-Bachá, R. S., Báez, E., GarcÃa-Segura, L. M., Jurado Coronel, J. C., Capani, F., Cardona-Gomez, G. P., & Barreto, G. E. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00211 · Cited by 449
Jo, D. H., Kim, J. H., Lee, T. G., & Kim, J. H. (2015) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2015.04.015 · Cited by 433
Use of Nanoparticles in Tissue Engineering and Regenerative Medicine
Fathi-Achachelouei, M., Knopf-Marques, H., Ribeiro da Silva, C. E., Barthès, J., Bat, E., Tezcaner, A., & Vrana, N. E. (2019) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2019.00113 · Cited by 390
Dinoff, A., Herrmann, N., Swardfager, W., & Lanctôt, K. L. (2017) · European Journal of Neuroscience · doi:10.1111/ejn.13603 · Cited by 323
“, 1998); however, evidence of the ability of BDNF to cross the BBB is inconsistent (Pardridge et al., 1994; Pilakka-Kanthikeel et al., 2013) and the human BBB is structurally and functionally different from those in animal”
Background
Metadata
- Authors
- Pilakka-Kanthikeel, S., Atluri, V. S. R., Sagar, V., Saxena, S. K., & Nair, M.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-04-30
- Volume
- 8
- Issue
- 4
- Pages
- e62241
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W1966943736
- Cited by
- 135
- References
- 7
- FWCI
- 5.15
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeted Brain Derived Neurotropic Factors (BDNF) Delivery across the Blood-Brain Barrier for Neuro-Protection Using Magnetic Nano Carriers: An In-Vitro Study. https://app.cochat.ai/papers/10.1371/journal.pone.0062241
- The paper
- Pilakka-Kanthikeel, S., Atluri, V. S. R., Sagar, V., Saxena, S. K., & Nair, M. (2013). Targeted Brain Derived Neurotropic Factors (BDNF) Delivery across the Blood-Brain Barrier for Neuro-Protection Using Magnetic Nano Carriers: An In-Vitro Study. PLoS ONE. https://doi.org/10.1371/journal.pone.0062241
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.